Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00339066 · ClinicalTrials.gov registry record · NA

Effect of Brain Lesion Severity on Treatment Response in Late-Life Depression

A NA study of Depression, sponsored by Duke University.

Completed
Registry status
NA
Development phase
131
Enrollment target
2
Study locations

NCT00339066: Completed NA study of Depression, sponsored by Duke University.

NCT00339066 is a NA study of Depression that has completed, run by Duke University. The registered enrollment target is 131 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (83% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00339066, a NA study of Depression, has completed, sponsored by Duke University.

COMPLETED
Registry status
NA
Development phase
131 participants
Enrollment target
2
Study locations

Study Summary

This study will determine the relationship between brain lesion severity, treatment response, and frontal lobe brain function in people with late-life depression (LLD).

Conditions Studied

Interventions

  • DRUG Sertraline

Study Locations (2)

Missouri

  • Washington University in St. Louis - St Louis

North Carolina

  • Duke University Medical Center - Durham

Trial Details

FieldValue
Enrollment Target 131 participants
Start Date 2001-08
Est. Completion 2006-03
Phase NA
Duke University

1,725 total trials

What the finished NCT00339066 record still lists

NCT00339066 is an interventional study that assigns participants to a tested intervention. The registered 131 participants enrollment target is mid-sized for trials with a published cap, below the 786-participant average among 679 other Depression trials with a reported enrollment target (83% lower).

The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 1 intervention - of which Sertraline is the first listed.

NCT00339066 reports a single indexed study location in Missouri, North Carolina.

Frequently Asked Questions

What is clinical trial NCT00339066 about?

NCT00339066 is a clinical study titled "Effect of Brain Lesion Severity on Treatment Response in Late-Life Depression". This study will determine the relationship between brain lesion severity, treatment response, and frontal lobe brain function in people with late-life depression (LLD).

What is the current status of trial NCT00339066?

This trial is currently completed. It is a NA study. The enrollment target is 131 participants. The study started on 2001-08. Estimated completion is 2006-03.

What conditions does trial NCT00339066 study?

This clinical trial studies the following conditions: Depression.

What interventions are being tested in trial NCT00339066?

The interventions under investigation include: Sertraline (DRUG).

Who is sponsoring clinical trial NCT00339066?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00339066 being conducted?

This trial has 2 study locations across Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00339066's enrollment target sits among peer trials

131 285th of 679 higher than 395 of 679 other Depression trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03051464 · 131 participants · Phase 2

    No Surgery Trial / Two Dose-escalation Strategies

  • NCT04301843 · 131 participants · Phase 2

    Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

  • NCT04748549 · 131 participants · NA

    Intraoperative VR for Older Patients Undergoing TKA

  • NCT05951179 · 131 participants · Phase 2

    Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00339066, the US trial registry maintained by the National Library of Medicine. NCT00339066 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.